Junior Underwriter

Resilience and Lilly invest $750 million to increase u.s.-manufactured medicine supply. Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market. This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership. By Catherine Hanley · September 14, 2026, 12:30 PM PDT · Pharmaceutical Manufacturing Resilience Pharmaceutical Eli Lilly Kwikpen Key takeaways $750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production 400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027 Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023 Get featured Want to get featured in MarketScale Sciences? Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required. Resilience and Eli Lilly are expanding their strategic partnership, which began in 2023, with a series of substantial investments aimed at bolstering U.S. pharmaceutical manufacturing. The collaboration, marked by a $750 million investment, focuses on increasing the production of Lilly's KwikPen(R), an injectable device used for diabetes and obesity medications. This move aligns with the surging demand for such treatments and aims to strengthen the availability of U.S.-manufactured medicines. Focused investment in Ohio manufacturing. The investment will enhance Resilience's manufacturing capabilities in the Cincinnati region, introducing Lilly's KwikPen production to its portfolio. This expansion is expected to create 400 high-skilled jobs, further elevating Resilience's impact in Ohio, where it already employs around 1,000 people across its advanced facilities. Preparation for the site expansion is in progress, with full operations anticipated by early 2027. The partnership between the two companies has already resulted in over 150 million doses of Lilly's medications being produced for the U.S. market. By leveraging proven technical capabilities and a steadfast commitment to quality, Resilience and Lilly aim to maintain the highest standards in domestic medicine supply. Edgardo Hernandez, Lilly's Executive Vice President, highlighted the need for scalability and reliability in meeting the growing demand for complex manufacturing programs. Strategic partnership and regional growth. This partnership underscores Ohio's emerging leadership in biomanufacturing, as recognized by Ohio Governor Mike DeWine, who cited Resilience's headquarters move to Blue Ash as evidence of the state's robust life sciences sector. Joining forces with entities like JobsOhio, REDI Cincinnati, and Ohio Life Sciences, Resilience contributes to a thriving pipeline of skilled manufacturing talent. These collaborations are part of broader efforts to sustain and grow the region's capacity in the life sciences industry. As Resilience continues to expand, its relationship with Lilly exemplifies how strategic partnerships can elevate both companies' capabilities while reinforcing the U.S. medicine supply chain. By focusing on disciplined execution and operational excellence, Resilience is establishing itself as a key player in addressing the needs of biopharma innovators and enhancing the U.S.'s role in global pharmaceuticals. Your experts belong here Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find. Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Lilly and Resilience invest $750M in diabetes and obesity drug device supply. July 31, 2026 | The investment will expand Resilience's U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines. Eli Lilly is expanding its partnership with service provider Resilience, with the pair committing $750 million to U.S. drug manufacturing capacity. The partners are using the cash to bolster Resilience's operations in the Cincinnati region. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. The contract development and manufacturing organization (CDMO) is preparing the site for expansion with the aim of starting full operations early next year. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies. May 13, 2026 Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. The addition of the new roles will bring the number of jobs created by Resilience in Ohio - where the CDMO has two sites around Cincinnati - up to 1,400. Resilience also has plants in Philadelphia and Toronto. The spend on the Ohio site continues Resilience's rapid rise. Launched in 2020 with more than $800 million from backers including Arch Venture Partners and 8VC, the CDMO went on to form pacts with companies including AstraZeneca, Sanofi and Takeda while raising almost $2.5 billion across two financing rounds, a debt deal and a loan from the U.S. Department of Defense. Resilience has used the money to add manufacturing capacity. The CDMO expanded a facility in West Chester, Ohio, in 2023; invested $225 million in a Cincinnati plant in 2024; and grew at two Ohio locations in 2025. In June, Resilience moved its corporate headquarters from San Diego to Blue Ash, Ohio, a northern suburb of Cincinnati. The company has partnered with JobsOhio to help staff the sites. The CDMO began working with Lilly in 2023. Resilience's archives lack a press release naming Lilly as a partner in 2023, although that year the CDMO did disclose a 10-year biomanufacturing alliance with an unnamed "leading pharmaceutical company." At the time, Resilience predicted the deal would support record revenues. Resilience has made more than 150 million doses of medicines for Lilly. Eli Lilly's latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization. May 8, 2026